The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level
- 8 October 2010
- journal article
- clinical trial
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 25 (1) , 21-27
Abstract
The aim of this study is to evaluate the potential and limitation of FDG-PET/CT for detecting prostate cancer in subjects with an elevated serum prostate-specific antigen (PSA) level. Although [18F]-2-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) has limited value in detecting prostate cancer, the potential of PET/CT has not been precisely evaluated, since positron emission tomography/computed tomography (PET/CT) provides accurate localization of functional findings obtained by PET. Subjects with an increasing PSA level suggestive of prostate cancer were enrolled in this study. FDG-PET/CT was performed prior to prostate biopsy and the findings were compared with the pathological results. Fifty subjects with an elevated serum PSA level took part in this study. The sensitivity, specificity and positive predictive value (PPV) of FDG-PET/CT in the prostate were 51.9% (27/52 areas), 75.7% (112/148 areas) and 42.9% (27/63 areas), respectively; those in the peripheral zone were 73.3% (22/30 areas), 64.3% (45/70 areas) and 46.8% (22/47 areas), respectively; and those in the central gland were 22.7% (5/22 areas), 85.9% (67/78 areas) and 31.3% (5/16 areas), respectively. The estimated cut-off values according to the highest odds ratio (OR) were age of 70 years [OR: 7.00, 95% confidence interval (CI): 1.89–25.93] and a PSA value of 12.0 ng/ml (OR: 10.77, 95% CI: 2.78–41.74). The FDG-PET/CT could potentially detect cancer with 80.0% sensitivity and 87.0% PPV in cases with a Gleason score of 7 or greater. FDG-PET/CT was appropriate for detecting peripheral zone prostate cancer in patients at more than an intermediate risk.Keywords
This publication has 24 references indexed in Scilit:
- Molecular Positron Emission Tomography and PET/CT Imaging in Urological MalignanciesEuropean Urology, 2007
- Imaging Prostate Cancer: A Multidisciplinary PerspectiveRadiology, 2007
- PROSTATE CANCER LOCALIZATION WITH 18 FLUORINE FLUOROCHOLINE POSITRON EMISSION TOMOGRAPHYJournal of Urology, 2005
- Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancerUrology, 2001
- Experience with carbon-11 choline positron emission tomography in prostate carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2000
- The Increased Accumulation of [18F]Fluorodeoxyglucose in Untreated Prostate CancerJapanese Journal of Clinical Oncology, 1999
- Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update1997
- Metabolic Imaging of Untreated Prostate Cancer by Positron Emission Tomography with sup 18 Fluorine-Labeled DeoxyglucoseJournal of Urology, 1996
- CT Depiction of Prostatic Zonal AnatomyJournal of Computer Assisted Tomography, 1992